AIDS 2010 18th International AIDS Conference (IAC) July 18-23 2010 Vienna, Austria

Conference Reports for NATAP


XIX International AIDS Conference July 22-27, 2012 Washington, DC

	HIV Treatment 19th International AIDS Conference July 22-27, 2012 Washington, D.C. - written by Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA (09/09/12) Metabolics/Inflammation and Such At IAC - written by David Alain Wohl, MD - The University of North Carolina (09/03/12) Co-Morbidities Report from 14th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV and XIX International AIDS Conference -Written by Todd Brown, MD, PhD Associate Professor of Medicine and Epidemiology Johns Hopkins University - (08/17/12) Immune Activation, Inflammation and Complications of HIV 19th IAC 2012: Written by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine - (07/31/12) HIV Prevention at AIDS 2012 -written Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (08/06/12) International AIDS Society (IAS) Symposium "Towards an HIV Cure" July 20-21 2012 Wash DC - written for NATAP by David Margolis MD, University of North Carolina - (08/06/12) New Agents for the Treatment of HIV-1: Is the pipeline opening up? - written by Joe Eron, MD University of North Carolina - (08/27/12) Effects of Raltegravir (RAL) Combined with Tenofovir (TDF) and Emtricitabine (FTC) on Body Shape, Bone Density and Lipids in HIV+ African-Americans Initiating Therapy: Metabolic Outcomes of The UNC-REAL Study - (09/04/12) Obese HIV-infected Persons have Higher Levels of Select Inflammatory Markers and Co-Morbid Illnesses - (09/03/12) Unexpected Complications: High 30 Day Readmission Rates among Persons Living with HIV - (09/03/12) Non-AIDS, AIDS events and death in a cohort of antiretroviral naïve HIV-infected patients with a CD4 T cell count above 500 cells/mm3 in Barcelona, Spain: nadir CD4 <350 & detectable viral load predict non-AIDS events: cancers/cardiovascular/neuropsych/liver/end-stage renal; "data suggest earlier ART could prevent nonAIDS events in viral controllers" - (09/03/12) Type 2 diabetes is associated with lower cognitive performances in a cohort of HIV-infected patients. ANRS CO3 Aquitaine Cohort, Bordeaux, France, 2007-2009 - (08/20/12) Severity of Illness and Fracture Risk: risk factors in HIV for bone fracture in Veterans & Aging Cohort/Men - (08/20/12) Associations of Inflammatory Markers with AIDS and non-AIDS Clinical Events after Initiation of Antiretroviral Therapy (ART): AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202 - (08/20/12) Effect of Second Generation Antipsychotics on Metabolic Variables in HIV-infected Adults on Long Term Antiretroviral Therapy - (08/17/12) Very Early Initiation of Combination Antiviral Therapy Results in Normalization of Markers of Immune Activation - (08/17/12) Carotid artery intima-media thickness and coronary artery calcium progress in HIV-infected participants over 6 years of follow-up - (08/15/12) Incidence and clinical features of cerebrovascular events in HIV-infected adults in the Southeastern United States - (08/15/12) HIV & Black MSM - (08/14/12) Will and Should Women in the U.S. Use PrEP? Findings from a Focus Group Study of At-risk HIV-negative Women in Oakland, Memphis, San Diego, and Washington, DC - (08/13/12) Tenofovir Plasma Pharmacokinetics in AIDS Clinical Trials Group Study A5202 - (08/10/12) Trends in Aggregate Plasma HIV RNA Levels at a Public Health HIV/AIDS Clinic in San Francisco from 2001-2011 - (08/09/12) Impact of single tablet regimens on the HIV switch market - (08/09/12) The clinical and economic impact of a generic first-line antiretroviral regimen in the U.S. - (08/09/12) Transmission of HIV-1 Exhibiting Resistance to Protease, Reverse Transcriptase and Integrase Inhibitors in a Previously Documented HIV-1 Negative Patient - (08/08/12) CDC Reports: Disparities in Health in HIV: "BLACKS TENDED TO HAVE WORSE CONTINUUM OF CARE COMPARED TO WHITES" - (08/08/12) SBI for HIV Diarrhea - (08/08/12) Exposure to nucleoside reverse transcriptase inhibitors (NRTIs) induces genotoxicity persistent for up to three years in Erythrocebus patas monkeys - (08/07/12) Low-Dose Aspirin for Activation: Increased platelet activity and immune activation in HIV-positive subjects on antiretroviral therapy is attenuated with low-dose aspirin - (08/06/12) Low Level Viral Load Detection in Blood and Mucosal Sites in Elite Controllers and HAART suppressed Women Enrolled in the Women's Interagency HIV (WIHS) Cohort - (08/06/12) Similar prevalence of baseline HIV-1 minority variants among responders and virologic failures, as well as increased detection of HIV-1 minority variants at treatment failure, in rilpivirine patients from the ECHO and THRIVE Phase III studies - (08/06/12) Prevalence of rilpivirine resistance-associated mutations in US samples received for routine resistance testing - (08/06/12) Gender Differences in Virologic Outcomes in a Meta-Analysis of Randomized Controlled Clinical Trials in HIV-1-Infected Patients on Antiretroviral Therapy - 'Women 28% Less Likely to Achieve <50 c/ml' - (08/06/12) A Meta-Analysis of the Differences in ART Virologic Failure Rates in Randomized Clinical Trials: Do Blacks Consistently Have Lower ART Efficacy and Poor Treatment Outcomes? - (08/06/12) 2 New Studies at IAC Finding 'Functional Cure' - (08/03/12) "scientists optimistic about a cure"......argument for treating patients with HAART early" - (08/03/12) HCV/HIV Coinfection Higher Rates of Hepatic Decompnsation, Liver Cancer & Severe Liver Events - (08/01/12) IMPAACT P1066: Raltegravir (RAL) safety and efficacy in HIV infected (+) youth 2 to 18 years of age through week 48 - (07/31/12) Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-Containing Regimens in HIV-Infected 4 Weeks to <2-Year-Old Children 48-Week Data From Study APV20002 - (07/31/12) Evidence of Coronary Vessel Wall Thickening in Asymptomatic Young HIV-Infected Patients Using Non-invasive MRI - (07/31/12) Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir-Containing Regimens in HIV-Infected 2 to 18 Year-Old Children (48-Week Data, Study APV29005, a Prospective, Open-label, Multi-centre, 48-Week Cohort Study) - (07/31/12) Drug Resistance and Mutational Profile in Fosamprenavir-Treated HIV-Infected Children Aged 2 Months to 18 Years at Start of Therapy - (07/31/12) HCV viremia affects immune phenotypes in Elite controllers of HIV infection- A Women's Interagency HIV Study - (07/30/12) HIV & Aging Plenary at IAC by Judy Currier: Intersection of Non-Communicable Diseases (comorbidities) and Ageing in HIV - (07/30/12) Stroke in human immunodeficiency virus (HIV) infected patients - (07/30/12) Slower Time to AIDS and TB in Immediate-Treatment Arm of HPTN 052 - Written by Mark Mascolini - (07/30/12) Predictors of HIV Transmission in a US Test-and-Treat Population: 29% in care don't use condoms - Written by Mark Mascolini - (07/30/12) Differences in CD4+ T-cell Immune Activation in HIV, Hepatitis C (HCV), and HIV/HCV Coinfection are Influenced by HIV and HCV Infection Status - (07/30/12) Incident bone fracture in men with, or at risk for, HIV-infection in the Multicenter AIDS Cohort Study (MACS), 1996-2011 - (07/30/12) Factors associated with elevated D-dimer levels in HIV-infected individuals: 'viral replication associated with D-dimer' - (07/30/12) Gold nanoparticles to improve drug delivery to the CNS: Targeting HIV reservoirs in the brain (raltegravir) - (07/30/12) A randomized trial to estimate efficacy and safety of 2 doses of raltegravir and efavirenz for treatment of HIV-TB co-infected patients : ANRS 12 180 REFLATE TB trial. - (07/27/12) Safety and efficacy of etravirine in HIV-1-infected, treatment-experienced children and adolescents: PIANO 48-week results - (07/27/12) Comorbidity and ageing with HIV A prospective comparative cohort study - (07/27/12) Low Rates of Integrase Resistance for Elvitegravir and Raltegravir through Week 96 in the Phase 3 Clinical Study GS-US-183-0145 - (07/27/12) Reduced skeletal muscle mitochondrial function in older HIV-infected men is associated with low aerobic exercise capacity - (07/27/12) Survey Challenges Assumptions About Aging With HIV in United States - Written by Mark Mascolini - (07/27/12) Aspirin Quiets Platelet and Immune Activation in Antiretroviral Responders - Written by Mark Mascolini - (07/27/12) Age at Stroke 15 Years Younger in HIV-Positives vs Negatives in New York City - Written by Mark Mascolini - (07/27/12) Non-AIDS Illness Rate Higher in Older HIV-Positives Than in Similar non-HIV Group - Written by Mark Mascolini - (07/27/12) Chances of Virologic Response Halved in Blacks vs Nonblacks in ART Trials - Written by Mark Mascolini - (07/27/12) Diabetes Linked to Poor Cognitive Function in HIV-Positive Adults - Written by Mark Mascolini - (07/27/12) Inflammation Markers Predict AIDS and non-AIDS Disease in ACTG Study - Written by Mark Mascolini - (07/27/12) A randomized trial to estimate efficacy and safety of 2 doses of raltegravir and efavirenz for treatment of HIV-TB co-infected patients : ANRS 12 180 REFLATE TB trial. - (07/27/12) Once-Daily Dolutegravir(DTG; S/GSK1349572) is Non-Inferior to Raltegravir (RAL) in Antiretroviral-naïve Adults. 48 Week results from SPRING-2 (ING113086) - (07/26/12) Effect of Early versus Delayed Initiation of Antiretroviral Therapy (ART) on Clinical Outcomes in the HPTN 052 Randomized Clinical Trial - (07/26/12) Adding Nitazoxanide to PEG/RBV Does Not Improve SVR With HIV/HCV Genotype 1 - Written by Mark Mascolini - (07/26/12) Maraviroc Plus Darunavir Vulnerable With Pretreatment Load Above 100,000? - Written by Mark Mascolini - (07/26/12) Good 4-Week Dolutegravir Response in Experienced Adolescents--PKs Comparable to Adults - Written by Mark Mascolini - (07/26/12) HIV Prevalence and Risks in a New Generation of US Injection Drug Users - Written by Mark Mascolini - (07/26/12) Systematic Review Finds HPV Doubles HIV Risk in Women and Men - Written by Mark Mascolini - (07/26/12) Quadrivalent HPV Vaccine Immunogenic in HIV+ Women With CD4s Over 200 - Written by Mark Mascolini - (07/26/12) Obesity Linked to Inflammation, cIMT, Low Vitamin D in US HIV Group - Written by Mark Mascolini - (07/26/12) Robust Response to Quadrivalent HPV Vaccine in Young HIV-Positive Women - Written by Mark Mascolini - (07/26/12) Mitochondrial Upsets May Underlie Metabolic Disorders in HIV-Positive Adolescents - Written by Mark Mascolini - (07/26/12) Depression Risk Steers MDs From EFV, But EFV Takers Still Have Higher Depression Rate - Written by Mark Mascolini - (07/26/12) Phase 1/2, Multicenter, Open-label, Pharmacokinetic, Safety, Tolerability, and Antiviral Activity Study of Dolutegravir (DTG), a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children, and Adolescents: P1093 - (07/26/12) Analysis of Efficacy by Baseline HIV RNA - Week 48 Results from a Phase 3 Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Quad) Compared to Efavirenz/Emtricitabine/Tenofovir DF in Treatment Naïve HIV-1 Infected Subjects - (07/26/12) Risk of common cancers by age 60 for HIV-infected patients in the United States and Canada - (07/26/12) ART Soon After Infection Yields Normal Immune Activation Markers in Small Study - Written by Mark Mascolini - (07/25/12) Timely ART Start Rates Climbing Steadily Across US and Canada - Written by Mark Mascolini - (07/25/12) Response to Etravirine Regimen in Experienced Children and Adolescents - Written by Mark Mascolini - (07/25/12) Raltegravir Formulations Effective for ART-Experienced Teens and Children - Written by Mark Mascolini - (07/25/12) Antiretroviral Treatment of Adult HIV Infection2012 Recommendations of the International Antiviral Society-USA Panel - (07/25/12) Long-Term Safety and Efficacy of Raltegravir (RAL)-Based VersusEfavirenz (EFV)-Based Combination Therapy in Treatment-Naïve HIV-1 Infected Patients:Final 5-Year Double-Blind Results from STARTMRK - (07/25/12) Final 5-Year Results of the BENCHMRK Studies: Sustained Antiretroviral Effect of Raltegravir, and Exploratory Analysis of Late Outcomes Based on Early Virologic Response - (07/25/12) THE HIV NRTI BMS-986001 DOES NOT DEGRADE MITOCHONDRIAL DNA IN LONG TERM PRIMARY CULTURES OF CELLS ISOLATED FROM HUMAN KIDNEY, MUSCLE AND SUBCUTANEOUS FAT - (07/25/12) Activity of the HIV-1 attachment inhibitor BMS-626529 against HIV-1 envelopes resistant to other entry inhibitors - (07/25/12) Analysis of Efficacy by Baseline Viral Load: Phase 3 Study Comparing Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Quad) versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF in Treatment Naïve HIV-1 Infected Subjects: Week 48 Results - (07/25/12) Absence of renal and bone toxicity in non-clinical studies of BMS-986001, a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus (HIV) - (07/25/12) Pharmacokinetics, Safety and Tolerability of the HIV Integrase Inhibitor S/GSK1265744 Long Acting Parenteral Nanosuspension Following Single Dose Administration to Healthy Adults - (07/25/12) Fractures at Earlier Age in HIV+ Men Versus HIV-Negatives in MACS - Written by Mark Mascolini - (07/24/12) PIs, Proton Pump Inhibitors, Stroke Raise Fracture Risk in HIV+ Veterans - Written by Mark Mascolini - (07/24/12) Mitochondrial Upsets May Underlie Metabolic Disorders in HIV-Positive Adolescents - Written by Mark Mascolini - (07/24/12) Observational Studies Confirm Preventive Impact of ART in HIV-Discordant Couples: transmission rate cut by 98% when CD4>350 - Written by Mark Mascolini - (07/24/12) Antiretroviral-Treated People in HPTN 052 Start Having Safer Sex - Written by Mark Mascolini - (07/24/12) Poor CD4 Responders Have Almost Doubled Risk of Non-AIDS Disease - Written by Mark Mascolini - (07/24/12) CD4 Count Under 700 Linked to All-Cause Mortality in Veterans Cohort - Written by Mark Mascolini - (07/24/12) Hospital Readmission Rate in HIV Group 44% Higher Than in US Population - Written by Mark Mascolini - (07/24/12) Maraviroc vs TDF/FTC + Reyataz/r - Written by Mark Mascolini - (07/24/12) Cobicistat Noninferior to Ritonavir as Atazanavir Booster at 48 Weeks - Written by Mark Mascolini - (07/24/12) Switch From Boosted PI to Single-Tablet Rilpivirine/TDF/FTC Maintains Suppression - Written by Mark Mascolini - (07/24/12) Elvitegravir Noninferior to Raltegravir at Week 96 in Treatment-Experienced - Written by Mark Mascolini - (07/24/12) Efficacy and Safety Results from a Randomized, Double-Blind, Active-Controlled Trial of Elvitegravir (Once-Daily) vs. Raltegravir (Twice-Daily) in Treatment-Experienced HIV-Infected Patients: Long Term 96-Week Data - (07/24/12) Cobicistat versus Ritonavir as Pharmacoenhancers in Combination with Atazanavir Plus Tenofovir DF/Emtricitabine: Phase 3 Randomized, Double Blind, Active-Controlled Trial, Week 48 Results - (07/24/12) SPIRIT Study: Switching boosted PI to Rilpivirine In Combination with Truvada as a Single-Tablet Regimen Week 24 Results (07/24/12)